Research

By D’Ann George, PhD, Medical Writer Dr. Eric Jonasch Positive Phase 1 Data on a “new class of drug” for ccRCC There has not been a new class of drugs for people with metastatic renal cell carcinoma (mRCC) since checkpoint inhibitors first entered clinical trials nearly a decade ago. At his poster presentation during the 2022 American Society of Clinical…

By D’Ann George, PhD, Medical Writer Racial and ethnic diversity in clinical trials, and the lack of it, was a major theme across research presented at the 2022 meeting of the American Society of Clinical Oncology, held in Chicago, Illinois on June 3-7. Trial participation is generally low among adults with cancer even though trials are an important way to…

Below are some highlights of the research presented at the 2022 meeting of the American Society of Clinical Oncology, which took place in Chicago, Illinois on June 3-7. Much of the kidney cancer data presented during the 2022 meeting of the American Society of Clinical Oncology (ASCO) expanded upon previous work and clarified how to continue refining clinical trial design…

Below are some of the research highlights from the 2022 American Urological Association's annual meeting held on May 13-16 in New Orleans, Louisiana.  Updated guidelines address new areas of renal mass management The AUA updated their guidelines on managing potentially cancerous renal masses in adults. The new version expands upon and clarifies several areas of management including: A multidisciplinary approach…

The KCA's 2022 International Kidney Cancer Symposium (IKCS): Europe was held from April 22-24 in Antwerp, Belgium. This symposium brought together top clinicians and researchers to share updates and discuss trends in kidney cancer. Read the coverage from a variety of publications. Uromigos Podcast 2022 IKCS: Europe Highlights with hosts Dr. Brian Rini and Dr. Tom Powles and guest Dr.…

Below are some of the research highlights from the American Society of Clinical Oncology (ASCO)’s 2022 Genitourinary Cancers Symposium, held on February 17-19 in San Francisco, California.  Dr. Rachel Giles of IKCC with their poster at ASCO GU 2022. Patients and families don’t always understand their diagnosis The International Kidney Cancer Coalition conducted a survey of the kidney cancer community…

2021 was a bumper year for kidney cancer developments, including several new treatment approvals by the FDA and a much better understanding of how kidney cancer is impacted by COVID-19 infections and vaccines. "All are very important topics that are affecting patients as we speak," said Nancy Moldawer, RN, of Cedars-Sinai Medical Center in Los Angeles, Ca, and a member…

Dr. Nirmish Singla received a 2021 Young Investigator Award for his project "Tumor evolution of brain-specific tropism in metastatic renal cell carcinoma." Singla is based at Johns Hopkins University in Baltimore, Maryland. We spoke with Singla about his work and what it could mean for people with kidney cancer. https://www.kidneycancer.org/the-kidney-cancer-association-awards-1-375-million-to-seven-teams-of-researchers/ Briefly describe your project. How did you develop this idea?…

Dr. Eric Kauffman received a 2021 Young Investigator Award for his project "Biology of spontaneously regressing renal cell carcinoma primary tumors." Kauffman is based at the Roswell Park Comprehensive Cancer Center in Buffalo, New York. We spoke with Kauffman about his work and what it could mean for people with kidney cancer. https://www.kidneycancer.org/the-kidney-cancer-association-awards-1-375-million-to-seven-teams-of-researchers/ How frequent is frequent when you say…

Dr. Elshad Hasanov received a 2021 Young Investigator Award for his project "Investigating genomic drivers of immune checkpoint inhibitors resistance in RCC brain metastasis: implications for immunotherapy." Hasanov is based at the MD Anderson Cancer Center in Houston, Texas. We spoke with Hasanov about his work and what it could mean for people with kidney cancer. https://www.kidneycancer.org/the-kidney-cancer-association-awards-1-375-million-to-seven-teams-of-researchers/ Briefly describe your…